HEALTH and regulatory officials on Monday said they would investigate allegations that doctor-investors at Bell-Kenz Pharma Inc. were prescribing hypertension and diabetes medication that the company imports as the Senate begins hearings on the controversy today.

Officials from the Department of Health (DoH), the Professional Regulation Commission (PRC), and the Food and Drug Administration (FDA) said they would jointly investigate reports of a 'pyramiding' scheme at the company and the use of luxurious gifts to entice doctors to prescribe their products.